Breast cancer CSCs have been identified by cell-surface marker combinations, most commonly CD44+CD24lo/−, as well as by expression of ALDH1 (Visvader and Lindeman, 2012), so we investigated the status of these CSC markers in our SORE6+ population. Here, CD44 is linked to breast carcinoma.